Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Non-Hodgkin's lymphoma (NHL) is the sixth most common cancer in the United Kingdom (UK). This analysis assessed the health service costs of patients receiving chemotherapy for indolent follicular NHL based on a retrospective analysis of patient records in the UK. Each patient was followed up for a period of 3 years or until death. The analysis included 181 patients, who received a total of 187 treatment periods. Costs were estimated from the perspective of the UK National Health Service. The study found the cost of providing treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or fludarabine to patients with indolent follicular NHL to be lower than previously reported.

Original publication

DOI

10.1159/000089462

Type

Journal article

Journal

Acta Haematol

Publication Date

2006

Volume

115

Pages

28 - 34

Keywords

Antineoplastic Combined Chemotherapy Protocols, Costs and Cost Analysis, Cyclophosphamide, Doxorubicin, Female, Follow-Up Studies, Health Services, Humans, Lymphoma, Follicular, Male, Middle Aged, Prednisone, Retrospective Studies, United Kingdom, Vidarabine, Vincristine